Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1B MULTICENTER, OPEN-LABEL, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF-06939926 IN AMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY

Next Previous
Trial Profile

A PHASE 1B MULTICENTER, OPEN-LABEL, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF-06939926 IN AMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fordadistrogene-movaparvovec (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Pfizer

    • Most Recent Events

    • 09 Nov 2022 Results investigating the impact fordadistrogene movaparvovec on physical functioning based on the Pediatric Outcomes Data Collection Instrument (PODCI), presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 26 Apr 2022 Planned End Date changed from 30 May 2026 to 30 Mar 2026.
    • 30 Mar 2022 Planned End Date changed from 15 May 2028 to 30 May 2026.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top